OpGen (NASDAQ:OPGN) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of OpGen (NASDAQ:OPGN) in a research note issued on Sunday. The firm set a “sell” rating on the medical research company’s stock.

OpGen Price Performance

Shares of NASDAQ:OPGN opened at $0.99 on Friday. The business’s 50 day simple moving average is $1.06 and its 200-day simple moving average is $1.46. OpGen has a 12 month low of $0.53 and a 12 month high of $9.90.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.